Protocol Ledger

NCT05607680 · Phase III · COMPLETED

A Study of IBI362 in Participants With Obesity or Overweight

Interventional Phase III clinical trial protocol NCT05607680 sponsored by Innovent Biologics (Suzhou) Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-14 Enrollment: 610 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05607680
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)610 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05607680
Protocol FieldVerified Registry Value
NCT IdentifierNCT05607680
Consolidated Lead SponsorInnovent Biologics (Suzhou) Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment610 participants (ACTUAL)
Registered Start Date2022-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI